CA2394416A1 - Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication - Google Patents
Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication Download PDFInfo
- Publication number
- CA2394416A1 CA2394416A1 CA002394416A CA2394416A CA2394416A1 CA 2394416 A1 CA2394416 A1 CA 2394416A1 CA 002394416 A CA002394416 A CA 002394416A CA 2394416 A CA2394416 A CA 2394416A CA 2394416 A1 CA2394416 A1 CA 2394416A1
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- composition
- gel
- active ingredient
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000000725 suspension Substances 0.000 title claims abstract description 4
- 239000004480 active ingredient Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 210000004400 mucous membrane Anatomy 0.000 title description 10
- 238000000034 method Methods 0.000 title description 2
- 210000004877 mucosa Anatomy 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 239000000227 bioadhesive Substances 0.000 claims abstract description 9
- 229920001983 poloxamer Polymers 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000003433 contraceptive agent Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- -1 hydroxypropyl Chemical group 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 abstract description 6
- 239000000499 gel Substances 0.000 description 19
- 230000009471 action Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229940124558 contraceptive agent Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical class CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000013008 thixotropic agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/15763 | 1999-12-14 | ||
| FR9915763A FR2802097B1 (fr) | 1999-12-14 | 1999-12-14 | Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication |
| PCT/FR2000/003533 WO2001043720A1 (fr) | 1999-12-14 | 2000-12-14 | Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2394416A1 true CA2394416A1 (fr) | 2001-06-21 |
Family
ID=9553244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002394416A Abandoned CA2394416A1 (fr) | 1999-12-14 | 2000-12-14 | Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030091642A1 (https=) |
| EP (1) | EP1237537B1 (https=) |
| JP (1) | JP2003516957A (https=) |
| AT (1) | ATE336987T1 (https=) |
| AU (1) | AU2525601A (https=) |
| CA (1) | CA2394416A1 (https=) |
| CY (1) | CY1106249T1 (https=) |
| DE (1) | DE60030319T2 (https=) |
| DK (1) | DK1237537T3 (https=) |
| ES (1) | ES2270895T3 (https=) |
| FR (1) | FR2802097B1 (https=) |
| PT (1) | PT1237537E (https=) |
| WO (1) | WO2001043720A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20031640A1 (it) | 2003-08-08 | 2005-02-09 | Mipharm S P A | Base per gel bioadesivi. |
| US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
| AU2004274000B2 (en) * | 2003-09-19 | 2009-07-30 | Drugtech Corporation | Pharmaceutical delivery system |
| US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
| CA2605341A1 (en) * | 2005-05-09 | 2006-11-16 | Drugtech Corporation | Modified-release pharmaceutical compositions |
| CN101374501A (zh) * | 2006-01-05 | 2009-02-25 | 药物技术公司 | 组合物及其使用方法 |
| US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252318A (en) * | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| JP2533723B2 (ja) * | 1992-12-28 | 1996-09-11 | 東興薬品工業株式会社 | 速乾性ゲルタイプ手指消毒剤 |
| ES2078175B1 (es) * | 1993-12-31 | 1996-10-16 | Cusi Lab | Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. |
| US5902110A (en) * | 1995-12-18 | 1999-05-11 | The Block Drug Company | Bone regeneration |
| US5869601A (en) * | 1996-04-05 | 1999-02-09 | S. C. Johnson & Son, Inc. | Method of stabilizing the viscosity of a thickened composition |
| EP1011609A4 (en) * | 1997-05-09 | 2000-08-16 | Medlogic Global Corp | COMPOSITIONS FOR COSMETIC APPLICATIONS |
| US7064114B2 (en) * | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
-
1999
- 1999-12-14 FR FR9915763A patent/FR2802097B1/fr not_active Expired - Fee Related
-
2000
- 2000-12-14 ES ES00988913T patent/ES2270895T3/es not_active Expired - Lifetime
- 2000-12-14 WO PCT/FR2000/003533 patent/WO2001043720A1/fr not_active Ceased
- 2000-12-14 DE DE60030319T patent/DE60030319T2/de not_active Expired - Lifetime
- 2000-12-14 DK DK00988913T patent/DK1237537T3/da active
- 2000-12-14 AT AT00988913T patent/ATE336987T1/de active
- 2000-12-14 JP JP2001544659A patent/JP2003516957A/ja active Pending
- 2000-12-14 EP EP00988913A patent/EP1237537B1/fr not_active Expired - Lifetime
- 2000-12-14 CA CA002394416A patent/CA2394416A1/fr not_active Abandoned
- 2000-12-14 US US10/149,695 patent/US20030091642A1/en not_active Abandoned
- 2000-12-14 PT PT00988913T patent/PT1237537E/pt unknown
- 2000-12-14 AU AU25256/01A patent/AU2525601A/en not_active Abandoned
-
2006
- 2006-11-16 CY CY20061101679T patent/CY1106249T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2270895T3 (es) | 2007-04-16 |
| PT1237537E (pt) | 2007-01-31 |
| DE60030319T2 (de) | 2007-08-30 |
| EP1237537B1 (fr) | 2006-08-23 |
| FR2802097B1 (fr) | 2002-12-13 |
| ATE336987T1 (de) | 2006-09-15 |
| FR2802097A1 (fr) | 2001-06-15 |
| DK1237537T3 (da) | 2006-12-27 |
| AU2525601A (en) | 2001-06-25 |
| JP2003516957A (ja) | 2003-05-20 |
| EP1237537A1 (fr) | 2002-09-11 |
| US20030091642A1 (en) | 2003-05-15 |
| WO2001043720A1 (fr) | 2001-06-21 |
| CY1106249T1 (el) | 2011-06-08 |
| DE60030319D1 (de) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2802816C (fr) | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur | |
| Gilhotra et al. | A clinical perspective on mucoadhesive buccal drug delivery systems | |
| CA2341814C (en) | Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues | |
| US20250332393A1 (en) | Devices and methods for the treatment of body surface disorders | |
| CN114206312A (zh) | 用于治疗炎性皮肤病的局部组合物和方法 | |
| EP0861067B1 (fr) | Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale | |
| EP0813412B1 (fr) | Gel pour hormonotherapie locale de la secheresse vaginale | |
| KR20110125660A (ko) | 가온성 및 무자극성 윤활제 항진균성 겔 조성물 | |
| CN107405360B (zh) | 新颖碘伏组合物及其使用方法 | |
| HK1243354A1 (en) | Novel iodophor composition and methods of use | |
| AU2018203882A1 (en) | Secnidazole for use in the treatment of bacterial vaginosis | |
| CA2304191A1 (en) | Topical non-steroidal anti-inflammatory drug composition | |
| KR20050025166A (ko) | 가온성 및 무자극성 윤활제 항진균성 겔 조성물 | |
| CA2394416A1 (fr) | Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication | |
| Patel et al. | Development and evaluation of in situ gelling system for treatment of periodontitis | |
| EP2200582B1 (fr) | Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant | |
| EP1711162B1 (fr) | Composition pour l'utilisation dans le traitement local des affections bucco-pharyngées comprenant de l'ibuprofène ou du kétoprofène | |
| EP4499041A1 (en) | Mirabegron formulation | |
| Patil et al. | A design of expert-based development and optimization of voriconazole-loaded aspasomal gel for topical delivery | |
| Bonam | Preparation and evaluation of pluronic lecithin organogel containing ricinoleic acid for transdermal drug delivery | |
| FR2703908A1 (fr) | Forme pharmaceutique pour administration rectale de composés pharmacologiquement actifs. | |
| WO2026060306A1 (en) | Compositions and uses of locally applied synthetic cationic and hydrophobic amino acid block copolymers, for prevention and treatment of bacterial and fungal infections | |
| HK40024783A (en) | Novel iodophor composition and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |